Charming Medical independent director resigns

Charming Medical Limited reported a change in its board leadership.

Rhea-AI Filing Summary

Charming Medical Limited reported a change in its board leadership. On March 27, 2026, independent director Ms. Josephine Yan Yeung resigned from the board to pursue other business commitments. The company stated her resignation was not due to any disagreement with its operations, policies, or procedures.

The board accepted and approved Ms. Yeung’s resignation on the same day. Charming Medical is actively identifying a suitable replacement and expects to fill the independent director vacancy by April 2, 2026, aiming to maintain continuity in its board oversight.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Charming Medical (MCTA) disclose in this March 2026 6-K?

Charming Medical disclosed the resignation of independent director Ms. Josephine Yan Yeung, effective March 27, 2026. The board accepted her resignation and the company is working to appoint a replacement director, targeting to fill the vacancy by April 2, 2026.

Why did Ms. Josephine Yan Yeung resign from Charming Medical (MCTA)?

Ms. Josephine Yan Yeung resigned as an independent director to pursue other business commitments. The company specifically stated that her decision was not due to any disagreement with its operations, policies, or procedures, indicating an orderly and non-contentious transition.

When was Ms. Yeung’s resignation from Charming Medical’s board effective?

Her resignation as an independent director became effective on March 27, 2026. On the same date, Charming Medical’s board of directors formally accepted and approved the resignation, making the board change effective immediately according to the company’s disclosure.

Did Ms. Yeung have any disagreements with Charming Medical (MCTA)?

The company stated that Ms. Yeung’s resignation was not the result of any disagreement with its operations, policies, or procedures. This language is commonly used to reassure investors that no underlying dispute or controversy prompted the board departure.

How will Charming Medical (MCTA) handle the vacant independent director seat?

Charming Medical is in the process of identifying a suitable replacement for Ms. Yeung’s independent director role. The company expects to fill the resulting board vacancy by April 2, 2026, suggesting a relatively quick transition to maintain board composition.

What is the significance of this board change for Charming Medical (MCTA)?

The filing highlights a routine board transition, with one independent director resigning and a replacement expected within days. Because the company reported no disagreements and plans a quick appointment, the change appears administrative rather than signaling a strategic shift.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 10:44 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42907

Charming Medical Limited

Units 1803-1806, 18/F, Hang Lung Centre
2-20 Paterson Street, Causeway Bay, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. Ms. Yeung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung’s resignation.

The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Charming Medical Limited
Date: March 27, 2026	By:	/s/ Kit Wong
	Name:	Kit Wong
	Title:	Chief Executive Officer and
		Chairman of the Board

2